阿替洛尔与拉贝洛尔对原发性高血压患者运动能力和血脂水平影响的比较研究。
A comparative study on the effect of atenolol and labetalol on exercise capacity and lipid serum levels in essential hypertension.
作者信息
Schamaun O, Westheim A, Qvigstad E K, Teisberg P
机构信息
Outpatient Clinic, Rikshospitalet, Oslo, Norway.
出版信息
Nephron. 1987;47 Suppl 1:135-7. doi: 10.1159/000184572.
Exercise performance was examined in 30 hypertensive subjects (mean age 43.2 +/- 5.4 years) in WHO group I-II, allocated to placebo, atenolol and labetalol treatment during a 3 X 12 weeks' exercise training period. Total work did not show any differences between the placebo and the two treatment periods. Compared to placebo, total cholesterol was reduced by 4.6% (p less than 0.04) in the labetalol and 3.1% (NS) in the atenolol period. Systolic and diastolic blood pressure were significantly reduced both at rest (p less than 0.01) and during exercise (p less than 0.01) in the two drug treatment periods compared to placebo.
对30名世界卫生组织I-II级高血压患者（平均年龄43.2±5.4岁）进行了运动表现测试，在为期3×12周的运动训练期间，这些患者被分配接受安慰剂、阿替洛尔和拉贝洛尔治疗。安慰剂组与两个治疗组之间的总运动量没有差异。与安慰剂相比，拉贝洛尔治疗期间总胆固醇降低了4.6%（p<0.04），阿替洛尔治疗期间降低了3.1%（无统计学意义）。与安慰剂相比，在两个药物治疗组中，静息时（p<0.01）和运动期间（p<0.01）收缩压和舒张压均显著降低。
Zotero 插件